ACTRN12612001105831
已完成
未知
Glucose facilitation of cognitive function: A placebo-controlled, double-blind, randomized, crossover trial in healthy older adults aged over 65
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Cognitive Function
- 发起方
- Swinburne University of Technology
- 入组人数
- 24
- 状态
- 已完成
- 最后更新
- 6年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Healthy non\-smoking males and females aged over 65
- •2\. No history of anxiety, depression, psychiatric disorders (confirmed using DASS) or epilepsy
- •3\. No history of / do not currently suffer from heart disease or high blood pressure or diabetes
- •4\. Not taking any medication, herbal extracts, vitamin supplements or illicit drugs which might reasonably be expected to interfere with blood glucose levels, for 4 weeks prior to (and duration of) study
- •5\. Not taking any form of medication within 5 days of admission (except for prophylactic antibiotics, or other routine medications to treat benign conditions, such as antibiotics to treat acne) and agree not to take any medication throughout the study
- •6\. No health conditions that would affect food metabolism including the following: food allergies, kidney disease, liver disease and/or gastrointestinal diseases (e.g. Irritable bowel syndrome, coeliac disease, peptic ulcers)
- •7\. Are willing and able to participate in all scheduled visits, treatment plan, dietary restrictions, tests and other trial procedures according to the protocol. Also comfortable with computers.
- •8\. Are willing to provide small finger prick blood samples and blood samples throughout the testing phases
- •9\. Absence of cognitive decline and a score \> 24 on the Mini Mental State Examination (MMSE)
- •10\. Understand the rating scales and computer tests (as judged by the study coordinator)
排除标准
- •2\. Diagnosis of Type 1 or Type 2 diabetes
- •3\. History of hypersensitivity to glucose
- •4\. History of anxiety, depression, psychiatric disorders or epilepsy
- •5\. History of / currently suffers from heart disease or high blood pressure or diabetes
- •6\. Evidence or history of any clinically significant (in the judgment of the investigator) renal, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, neurological, within the last 5 years
- •7\. Use of any over\-the\-counter herbal extracts, vitamin supplements and/or other dietary supplements which might influence glucose absorption or metabolism for four weeks prior to the practice day
- •8\. Taking any illicit drugs
- •9\. Health conditions that would affect food metabolism including the following: food allergies, kidney disease, liver disease and/or gastrointestinal diseases (e.g. have Irritable bowel syndrome, peptic ulcers)
- •10\. Are not willing to provide small finger prick blood samples throughout the testing phases
- •11\. Current participation in any other trials involving investigational or marketed products within 30 days prior to the practice day.
结局指标
主要结局
未指定
相似试验
已完成
不适用
Cognitive performance in relation to glucose toleranceglucose sensitivityinsulin resistance10018424NL-OMON34345TNO30
尚未招募
不适用
Relation of glucose control with cognition in type 2 diabetes patientsHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2024/03/063508Maulana Azad Medical College
已完成
不适用
Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease PatientsParkinson DiseaseNCT00004451National Institute of Mental Health (NIMH)120
已完成
不适用
Glucose-induced performance changes and possible moderatorsEffect of glucose consumption on cognitive parametersDRKS00019843Bergische Universität Wuppertal75
已完成
不适用
Cognitive and mood effects of saccharides in middle-aged adultsACTRN12610000624088Dr Talitha Best80